HC Wainwright & Co. Maintains Buy Rating for Jazz Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) but lowered its price target from $204 to $200. Despite this, shares of Jazz Pharmaceuticals have seen a slight increase of 0.2% in the last 24 hours, trading at $118 per share. A move to the new price target would represent a 69.49% increase from the current share price. Jazz Pharmaceuticals, an Ireland-based biopharmaceutical company, focuses on treatments for sleeping disorders and oncology, with nine approved drugs in its portfolio.
March 14, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating for Jazz Pharmaceuticals but lowers its price target from $204 to $200. The stock has seen a slight increase of 0.2% in the last 24 hours, trading at $118.
The maintenance of a Buy rating by HC Wainwright & Co. indicates a positive outlook on Jazz Pharmaceuticals, despite the slight decrease in the price target. The slight increase in share price following the announcement suggests a positive market reaction in the short term. The adjustment in price target, while lower, still suggests a significant potential upside, indicating continued confidence in the company's future performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100